335 related articles for article (PubMed ID: 16715415)
1. Striatal metabotropic glutamate receptors as a target for pharmacotherapy in Parkinson's disease.
Bonsi P; Cuomo D; Picconi B; Sciamanna G; Tscherter A; Tolu M; Bernardi G; Calabresi P; Pisani A
Amino Acids; 2007 Feb; 32(2):189-95. PubMed ID: 16715415
[TBL] [Abstract][Full Text] [Related]
2. An influence of ligands of metabotropic glutamate receptor subtypes on parkinsonian-like symptoms and the striatopallidal pathway in rats.
Ossowska K; Konieczny J; Wardas J; Pietraszek M; Kuter K; Wolfarth S; Pilc A
Amino Acids; 2007 Feb; 32(2):179-88. PubMed ID: 16699817
[TBL] [Abstract][Full Text] [Related]
3. The influence of group III metabotropic glutamate receptor stimulation by (1S,3R,4S)-1-aminocyclo-pentane-1,3,4-tricarboxylic acid on the parkinsonian-like akinesia and striatal proenkephalin and prodynorphin mRNA expression in rats.
Konieczny J; Wardas J; Kuter K; Pilc A; Ossowska K
Neuroscience; 2007 Mar; 145(2):611-20. PubMed ID: 17224239
[TBL] [Abstract][Full Text] [Related]
4. The role of striatal metabotropic glutamate receptors in Parkinson's disease.
Ossowska K; Konieczny J; Wardas J; GoĊembiowska K; Wolfarth S; Pilc A
Amino Acids; 2002; 23(1-3):193-8. PubMed ID: 12373537
[TBL] [Abstract][Full Text] [Related]
5. The role of striatal metabotropic glutamate receptors in degeneration of dopamine neurons: review article.
GoĊembiowska K; Konieczny J; Ossowska K; Wolfarth S
Amino Acids; 2002; 23(1-3):199-205. PubMed ID: 12373538
[TBL] [Abstract][Full Text] [Related]
6. Role of metabotropic glutamate receptors in animal models of Parkinson's disease.
Senkowska A; Ossowska K
Pol J Pharmacol; 2003; 55(6):935-50. PubMed ID: 14730087
[TBL] [Abstract][Full Text] [Related]
7. Selective activation of group III metabotropic glutamate receptors by L-(+)-2-amino-4-phosphonobutryic acid protects the nigrostriatal system against 6-hydroxydopamine toxicity in vivo.
Vernon AC; Zbarsky V; Datla KP; Dexter DT; Croucher MJ
J Pharmacol Exp Ther; 2007 Jan; 320(1):397-409. PubMed ID: 17012606
[TBL] [Abstract][Full Text] [Related]
8. The role of NMDA and GABAA receptors in the inhibiting effect of 3 MPa nitrogen on striatal dopamine level.
Lavoute C; Weiss M; Rostain JC
Brain Res; 2007 Oct; 1176():37-44. PubMed ID: 17900538
[TBL] [Abstract][Full Text] [Related]
9. Paraquat inhibits postsynaptic AMPA receptors on dopaminergic neurons in the substantia nigra pars compacta.
Lee CY; Lee CH; Shih CC; Liou HH
Biochem Pharmacol; 2008 Oct; 76(9):1155-64. PubMed ID: 18761327
[TBL] [Abstract][Full Text] [Related]
10. Functional interactions between somatodendritic dopamine release, glutamate receptors and brain-derived neurotrophic factor expression in mesencephalic structures of the brain.
Bustos G; Abarca J; Campusano J; Bustos V; Noriega V; Aliaga E
Brain Res Brain Res Rev; 2004 Dec; 47(1-3):126-44. PubMed ID: 15572168
[TBL] [Abstract][Full Text] [Related]
11. Limited regulation of somatodendritic dopamine release by voltage-sensitive Ca channels contrasted with strong regulation of axonal dopamine release.
Chen BT; Moran KA; Avshalumov MV; Rice ME
J Neurochem; 2006 Feb; 96(3):645-55. PubMed ID: 16405515
[TBL] [Abstract][Full Text] [Related]
12. Levodopa enhances synaptic plasticity in the substantia nigra pars reticulata of Parkinson's disease patients.
Prescott IA; Dostrovsky JO; Moro E; Hodaie M; Lozano AM; Hutchison WD
Brain; 2009 Feb; 132(Pt 2):309-18. PubMed ID: 19050033
[TBL] [Abstract][Full Text] [Related]
13. Disturbances in neurotransmission processes in aging and age-related diseases.
Ossowska K
Pol J Pharmacol; 1993; 45(2):109-31. PubMed ID: 8401765
[TBL] [Abstract][Full Text] [Related]
14. Transplantation of autologous sympathetic neurons as a potential strategy to restore metabolic functions of the damaged nigrostriatal dopamine nerve terminals in Parkinson's disease.
Nakao N; Shintani-Mizushima A; Kakishita K; Itakura T
Brain Res Rev; 2006 Sep; 52(2):244-56. PubMed ID: 16644019
[TBL] [Abstract][Full Text] [Related]
15. Neuroprotective effects of metabotropic glutamate receptor ligands in a 6-hydroxydopamine rodent model of Parkinson's disease.
Vernon AC; Palmer S; Datla KP; Zbarsky V; Croucher MJ; Dexter DT
Eur J Neurosci; 2005 Oct; 22(7):1799-806. PubMed ID: 16197521
[TBL] [Abstract][Full Text] [Related]
16. NMDA receptors mediate an early up-regulation of brain-derived neurotrophic factor expression in substantia nigra in a rat model of presymptomatic Parkinson's disease.
Bustos G; Abarca J; Bustos V; Riquelme E; Noriega V; Moya C; Campusano J
J Neurosci Res; 2009 Aug; 87(10):2308-18. PubMed ID: 19326433
[TBL] [Abstract][Full Text] [Related]
17. Alterations in nigral NMDA and GABAA receptor control of the striatal dopamine level after repetitive exposures to nitrogen narcosis.
Lavoute C; Weiss M; Rostain JC
Exp Neurol; 2008 Jul; 212(1):63-70. PubMed ID: 18452916
[TBL] [Abstract][Full Text] [Related]
18. Antagonism of metabotropic glutamate receptor type 5 attenuates l-DOPA-induced dyskinesia and its molecular and neurochemical correlates in a rat model of Parkinson's disease.
Mela F; Marti M; Dekundy A; Danysz W; Morari M; Cenci MA
J Neurochem; 2007 Apr; 101(2):483-97. PubMed ID: 17359492
[TBL] [Abstract][Full Text] [Related]
19. Pharmacological regulation of striatal gene expression by metabotropic glutamate receptors.
Wang JQ; Mao LM
Zhongguo Yao Li Xue Bao; 1999 Jul; 20(7):577-84. PubMed ID: 10678116
[TBL] [Abstract][Full Text] [Related]
20. Immunohistochemical detection of L-DOPA-derived dopamine within serotonergic fibers in the striatum and the substantia nigra pars reticulata in Parkinsonian model rats.
Yamada H; Aimi Y; Nagatsu I; Taki K; Kudo M; Arai R
Neurosci Res; 2007 Sep; 59(1):1-7. PubMed ID: 17586078
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
